Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

Interim data from Phase 1b Study indicate that adecatumumab in combination with docetaxel is safe and well tolerated and suggest a better outcome for

breast cancer patients with high EpCAM expression

BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented interim data from a study investigating its anti-EpCAM antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel(1) on Saturday, September 13 at the 2008 meeting of the European Society of Medical Oncology (ESMO) held in Stockholm, Sweden.

Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be associated with poor prognosis for many solid cancers. A previous phase 2 trial investigating adecatumumab as a single agent in patients with metastatic breast cancer (MBC) suggested that treatment with adecatumumab was associated with fewer new metastases in patients with high EpCAM expression compared to patients with low EpCAM expression(2).

The ongoing phase 1b clinical trial presented at ESMO investigated the safety and tolerability of increasing doses of adecatumumab in combination with standard chemotherapy docetaxel in relapsed MBC patients who had a median of three prior chemotherapy regimens. Combining adecatumumab with docetaxel appears to be feasible with clinically manageable diarrhea being the main toxicity at higher doses. Other frequently observed adverse events included nausea, vomiting, stomatitis, constipation, fatigue, fever and chills. No increase in adverse events or laboratory abnormalities typically seen with docetaxel was observe
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... , May 25 Informed Medical ... medical forums and integrated medical communications for the ... initiative, responding to the FDA,s new program to ... level of complexity the FDA,s "Bad Ad Program" ...
... , May 25 Stryker’s Communications business unit and ... integrate both companies’ technologies within the operating room to provide customers ... solutions. , , ... Stryker’s Infinity Control System allows staff within the OR to route ...
Cached Medicine Technology:Informed Medical Communications Takes the Lead in Response to FDA's 'Bad Ad Program' 2Stryker Enters Strategic Marketing Agreement with Acuitec 2Stryker Enters Strategic Marketing Agreement with Acuitec 3
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping ... items. During the holiday season, AlignLife looks forward to their ... says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our ... that we are able to give kids toys for Christmas ... for the generosity of our patients." , The 70 toys ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Newer Single-Pill Fixed Combination Brands, According to a New ... , NASHVILLE, Tenn., Dec. 10 HealthLeaders-InterStudy, ... that although Novartis, Exforge and Tekturna have slowly penetrated ... over the last 12 months, their progress has stalled. ...
... Finding Dr. Right brings together in one resource the necessary information to ... time of year , ... Lyndhurst, NJ (PRWEB) December 10, 2008 -- ... figuring out what an otolaryngologist is), navigating the medical landscape can be ...
... Mobile System to Launch in Three Skilled Nursing Facilities ... Dec. 10 After an intense 18-month selection process, ... contract to deploy electronic medical records (EMR) throughout Metropolitan ... , Metropolitan, a nationally ...
... Inc., the world,s leading manufacturer and distributor of automated blood ... Consulting, an expert in Internet software development, team-up to launch ... ... Burtonsville, MD (PRWEB) December 10, 2008 -- ...
... Phase II Cancer Trials and the Company,s Other Clinical Programs All ... - Significant Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral ... - Company Enters into Loan Agreement for Up to ... TUSTIN, Calif., Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... Dec. 10 Michael Merzenich, PhD, a leading ... the Chief Scientist of Posit Science Corporation, gave ... of a joint conference of the Netherlands Institute ... Arts and Science in Amsterdam. His talk, ...
Cached Medicine News:Health News:Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market 2Health News:Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market 3Health News:Vitals Launches Free eBook to Help Consumers Find "Dr. Right" 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:Lifeclinic International and Get Real Consulting Team-Up to Launch Microsoft's HealthVault 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Posit Science Co-Founder and Brain Plasticity Pioneer, Michael Merzenich, Speaks at Science Conference in the Netherlands 2
... Stand Magnifier offers versatility across a ... lens and the light are adjustable. ... hand held objects can be worked ... parallel to the work surface, lay ...
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
... Piston assembly fits into neck of platform ... ready position after use. Cutting block fits ... disposable trephine blades sized 6.25 - 9.0 ... the preparation of corneal donor buttons for ...
... allows the surgeon to effectively ... scrub-resistant, gentian violet ink. All ... sterile, with a ruler and ... pouches. Micro tip marker for ...
Medicine Products: